Stock analysts at StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the stock.
Trinity Biotech Trading Down 2.4 %
Shares of NASDAQ TRIB opened at $0.75 on Friday. The stock has a market capitalization of $13.61 million, a PE ratio of -0.33 and a beta of 0.86. The stock has a fifty day simple moving average of $0.65 and a 200-day simple moving average of $0.92. Trinity Biotech has a twelve month low of $0.48 and a twelve month high of $3.55.
Institutional Trading of Trinity Biotech
An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC lifted its position in shares of Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 5.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 378,590 shares of the company’s stock after buying an additional 18,780 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent quarter. Institutional investors own 78.97% of the company’s stock.
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Recommended Stories
- Five stocks we like better than Trinity Biotech
- Why Invest in 5G? How to Invest in 5G Stocks Â
- IBM’s AI Offensive: Assessing IBM’s Path to Renewed Growth
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Rockwell Automation: Tailwinds From Onshoring U.S. Production
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Is Energy Transfer Undervalued or a Value Trap?
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
